LEXINGTON, Mass., Aug 01, 2011 (BUSINESS WIRE) —
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company
focused on the development and commercialization of a therapeutic iron
compound to treat iron deficiency anemia, today announced the
appointment of Frank E. Thomas to the position of Executive Vice
President and Chief Financial Officer. Mr. Thomas, age 41, will be
responsible for the Company’s finance, accounting, treasury and
corporate communications functions and will report directly to Brian
J.G. Pereira, M.D., President and CEO.
During his 19-year career, Mr. Thomas has held a variety of senior
executive roles in the life sciences industry. From 2008 to 2011, Mr.
Thomas served as Senior Vice President, Chief Operating Officer and
Chief Financial Officer for Molecular Biometrics, a medical diagnostics
company focused on reproductive medicine where he established the
company’s manufacturing, distribution and business processes in support
of product development and commercialization. Prior to his time with
Molecular Biometrics, Mr. Thomas spent four years at Critical
Therapeutics, Inc., where he was promoted to President and Chief
Executive Officer from the position of Senior Vice President and Chief
Financial Officer to lead a turnaround effort, refocus the company on
new product opportunities and improve operational execution. Mr. Thomas
also served on the Board of Directors of Critical Therapeutics until
2008. Prior to 2004, he served as Chief Financial Officer and Vice
President of Finance and Investor Relations at Esperion Therapeutics,
Inc., a development-stage biotechnology company focused on a
cardiovascular product portfolio where he contributed to the advancement
of Esperion’s product portfolio and supported the company through its
eventual $1.3 billion acquisition by Pfizer, Inc. Since 2007, Mr. Thomas
has been a member of the Board of Directors of the Massachusetts
Biotechnology Council.
“Frank’s broad experience in senior leadership positions of commercial
public companies, particularly his commercial insights and ability to
successfully lead through transitions, will be a valuable asset to AMAG
and our shareholders,” said Brian J. G. Pereira, M.D., President and
Chief Executive Officer of AMAG Pharmaceuticals, Inc. “I am pleased to
welcome Frank to AMAG.”
Mr. Thomas’s prior positions include senior director of finance,
corporate controller and audit roles with Mechanical Dynamics Inc., and
Arthur Anderson LLP from 1992 to 2000, respectively. Mr. Thomas holds a
B.B.A. in Business Administration from the University of Michigan, Ann
Arbor.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
development and commercialization of a therapeutic iron compound to
treat iron deficiency anemia. For additional company information, please
visit www.amagpharma.com.
SOURCE: AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals
Carol Miceli, 617-498-3361
